Press Releases
-
May 19, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Citi Global Healthcare Conference in New York...
-
May 12, 2010
BioMarin Pharmaceutical Inc. today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Baird Growth Stock Conference in Chicago on Wednesday,...
-
May 4, 2010
BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the JMP Securities Research Conference in...
-
Apr 29, 2010First Quarter Profitability Driven by Continued Growth of Naglazyme Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited) Item Q1 2010 Q1 2009 Comparison Total BioMarin Revenue $85.0 14.8% increase Total Net Product Revenue $84.1 16.9% increase...
-
Apr 29, 2010GALNS Demonstrates Benefits in Endurance and Pulmonary Function Endpoints Phase III Trial Expected to Start by Q4 2010 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. today announced positive results for the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage...
-
Apr 28, 2010
BioMarin Pharmaceutical Inc. today announced that Steve Aselage, Executive Vice President and Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank 35th Annual...
-
Apr 19, 2010
BioMarin Pharmaceutical Inc. announced today that Firdapse(TM) (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease...
-
Apr 1, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29, at 5:00 p.m. ET to...
-
Mar 17, 2010
BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
-
Mar 2, 2010
BioMarin Pharmaceutical Inc. today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Cowen and Company 30th Annual Health Care Conference in...
-
Feb 25, 2010International Coalition Aims to Increase Public Awareness, Supportive Legislation and Drug Development For Patients with Rare Diseases; California Assembly Endorses State Date of Observance
BioMarin Pharmaceutical Inc. announced today that it has partnered with industry and patient advocacy organizations in an international effort to raise awareness of rare diseases which affect...
-
Feb 23, 2010Fourth Quarter Profitability Driven by Continued Growth of Naglazyme and Kuvan Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data) Item FY 2009 FY 2008 Comparison Total BioMarin Revenue $324.7 9.5% increase Total Net Product Revenue $315.7 25.4% increase Naglazyme...
-
Feb 4, 2010Expectations for Continued Double Digit Revenue Growth and Positive Cash Flow Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. today announced 2010 financial guidance. The reconciliation of the non-GAAP measures to the estimated GAAP net income is detailed in the table provided in the press...
-
Feb 4, 2010Key Asset is LT-673, PARP Inhibitor for the Treatment of Genetically Defined Cancers Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage...
-
Feb 4, 2010Phase III Trial Expected to Start by Q4 2010 or Q1 2011 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage...
-
Feb 2, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 12th Annual BIO CEO and Investor Conference in...
-
Feb 2, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, February 23, at 5:00 p.m. ET to...
-
Jan 11, 2010
BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in the Phase 1 clinical study of BMN 195, a small molecule utrophin upregulator, for the treatment of...
-
Jan 5, 2010
BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert...
-
Jan 5, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 28th Annual J.P. Morgan Healthcare Conference in...
-
Nov 30, 2009
BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the...
-
Nov 24, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the NASDAQ OMX 23rd Investor Program in London on...
-
Nov 13, 2009
BioMarin Pharmaceutical Inc. announced today that Genzyme notified the company that, in rare circumstances, it has detected foreign particles in some products filled at the Allston Landing...
-
Nov 5, 2009
BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan® (sapropterin dihydrochloride)...
-
Nov 4, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on...
-
Oct 28, 2009Third Quarter Results Drive Improved 2009 Net Income Guidance Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data) Item Q3 2009 Q3 2008 Comparison Total BioMarin Revenue $80.8 11% increase Total Net Product Revenue $78.4 16% increase Naglazyme Net...
-
Oct 27, 2009
BioMarin Pharmaceutical Inc. today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Oppenheimer Healthcare Conference in New York City on...
-
Oct 26, 2009Sole Product of Huxley is a Proprietary Form of 3,4-Diaminopyridine, Amifampridine Phosphate Positive Opinion for Approval of Amifampridine Phosphate for the Treatment of Lambert Eaton Myasthenic Syndrome (LEMS) Issued by European Regulatory Authorities on October 23, 2009 Official Approval and Product Launch Expected in Q1 2010 Conference Call and Webcast to Be Held Today at 5:30 p.m. ET
BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine...
-
Oct 9, 2009
BioMarin Pharmaceutical Inc. announced today that its Chief Executive Officer Jean-Jacques Bienaime will receive the Most Admired CEO Award from the San Francisco Business Times at a gala event to...
-
Sep 30, 2009
BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has allowed claims covering the approved administration of Kuvan® (sapropterin dihydrochloride)...
-
Sep 30, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 28, at 5:00 p.m. ET to...
-
Sep 22, 2009
BioMarin Pharmaceutical Inc. announced today that the first patient has initiated treatment in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the...
-
Sep 15, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New York...
-
Sep 8, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Healthcare Conference in New York...
-
Sep 2, 2009
BioMarin Pharmaceutical Inc. today announced that Hank Fuchs, M.D., Senior Vice President and Chief Medical Officer of BioMarin, will present a company update at the Baird Healthcare Conference in...
-
Sep 2, 2009
BioMarin Pharmaceutical Inc. today announced that Jeffrey H. Cooper, Senior Vice President and Chief Financial Officer of BioMarin, will present a company update at the Thomas Weisel Partners...
-
Aug 19, 2009
BioMarin Pharmaceutical Inc. announced today that data from clinical studies of Kuvan (sapropterin dihydrochloride) and Naglazyme (galsulfase) will be presented at the 11th Annual Meeting of the...
-
Jul 30, 2009Net Product Revenue Increase of 35% Drives Profitable Quarter Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET)
Financial Highlights ($ in millions, except per share data) Item Q2 2009 Q2 2008 Comparison Total BioMarin Revenue $82.8 29% increase Total Net Product Revenue $81.5 35% increase Naglazyme Net...
-
Jul 30, 2009
BioMarin Pharmaceutical Inc. announced today that the United States Patent Office has issued patents covering stable tablet formulation and the approved once daily dosing regimen for Kuvan...
-
Jul 13, 2009
BioMarin Pharmaceutical Inc. announced today that patient enrollment has been completed for the Phase I/II clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the...
-
Jul 1, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET (23:00...
-
Jun 16, 2009
BioMarin Pharmaceutical Inc. announced today that the temporary interruption of bulk production at Genzyme's Allston Landing manufacturing facility is not expected to have any impact on Aldurazyme...
-
Jun 10, 2009
BioMarin Pharmaceutical Inc. today announced that Steve Aselage, Senior Vice President and Chief Business Officer of BioMarin, will present a company update at the Jefferies Healthcare Conference...
-
Jun 10, 2009
BioMarin Pharmaceutical Inc. announced today that it has received notice of priority review status for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for patients with phenylketonuria...
-
Jun 9, 2009
BioMarin Pharmaceutical Inc. today announced results from the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). The...
-
Jun 3, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago...
-
Jun 2, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Goldman Sachs 30th Annual Global Healthcare...
-
May 15, 2009National Organization for Rare Disorders (NORD) Recognizes BioMarin's Efforts to Expand Treatment Options for Patients with PKU
BioMarin Pharmaceutical Inc. announced today that it has received the 2009 Corporate Award from the National Organization for Rare Disorders (NORD), an organization dedicated to improving the...
-
May 12, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Deutsche Bank 34th Annual Health Care Conference...
-
May 7, 2009
BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Baird Growth Stock Conference...
-
Apr 30, 2009Net Product Revenue Increase of 25% Led by Naglazyme International Expansion
Financial Highlights ($ in millions, except per share data) Item Q1 2009 Q1 2008 Comparison Total BioMarin Revenue $74.0 23% increase Total Net Product Revenue $71.9 25% increase Naglazyme Net...
-
Apr 21, 2009
BioMarin Pharmaceutical Inc. announced today the initiation of a Phase 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal...
-
Apr 9, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 30, at 5:00 p.m. ET (23:00...
-
Mar 30, 2009
BioMarin Pharmaceutical Inc. announced today that it has received a notice from the United States Patent Office reporting allowance of claims covering once daily dosing methods for Kuvan(R)...
-
Mar 25, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 4th Annual Citi Biotech Day in New York City on...
-
Mar 18, 2009
BioMarin Pharmaceutical Inc. announced today that its application for clinical trial authorization (CTA) for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the...
-
Mar 10, 2009
BioMarin Pharmaceutical Inc. today announced that Jeffrey H. Cooper, Senior Vice President and Chief Financial Officer of BioMarin, will present a company update at the Cowen and Company 29th...
-
Mar 4, 2009
BioMarin Pharmaceutical Inc. today announced that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the Barclays Capital Global...
-
Mar 3, 2009Has No Foreseeable Impact on Aldurazyme Sales
BioMarin Pharmaceutical Inc. announced today that the FDA warning letter issued to Genzyme addressing deficiencies related to Genzyme's Allston Landing manufacturing facility during an inspection...
-
Mar 2, 2009
BioMarin Pharmaceutical Inc. announced today the appointment of Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer (CMO). Dr. Fuchs will replace longtime BioMarin CMO, Dr. Emil...
-
Feb 26, 2009Worldwide Coalition Seeks to Increase Public Awareness and Research to Improve Medical Care for Patients Lacking Adequate Treatment Options
BioMarin Pharmaceutical Inc. announced today that it will participate in a coalition of organizations led by the National Organization for Rare Disorders (NORD) to support the observance of Rare...
-
Feb 18, 20092008 First Profitable Full Year
Financial Highlights ($ in millions, except per share data) Item FY 2008 FY 2007 Comparison Total BioMarin Revenue $296.5 143.9% increase Naglazyme Net Product Revenue $132.7 53.9% increase...
-
Feb 12, 2009
BioMarin Pharmaceutical Inc. announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that...
-
Feb 3, 2009
BioMarin Pharmaceutical Inc. announced today that ANVISA, Brazil's National Health Surveillance Agency, has granted BioMarin marketing approval for Naglazyme(R) (galsulfase) for the treatment of...
-
Feb 3, 2009
BioMarin Pharmaceutical Inc. today announced results from its Phase 2 multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral...
-
Jan 28, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 18, at 5:00 p.m. ET...
-
Jan 7, 2009
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 27th Annual J.P. Morgan Healthcare Conference in...
-
Jan 6, 2009Riquent is Currently Being Evaluated in a Phase 3 Clinical Study for Lupus Nephritis, A High Unmet Need and Orphan Disease
BioMarin Pharmaceutical Inc. and La Jolla Pharmaceutical Company announced today that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug...
-
Dec 9, 2008
BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received marketing approval for Kuvan(R) (sapropterin dihydrochloride)...
-
Nov 25, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in New York...
-
Nov 21, 2008
BioMarin Pharmaceutical Inc. today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009. Dr. Kakkis has decided to leave his position with...
-
Nov 6, 2008
BioMarin Pharmaceutical Inc. announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase) and enzyme replacement therapies for MPS IVA...
-
Nov 5, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse 2008 Annual Healthcare Conference...
-
Nov 3, 2008
BioMarin Pharmaceutical Inc. announced today the initiation of the Morquio Clinical Assessment Program (MorCAP) for patients with the lysosomal storage disease Mucopolysaccharidosis Type IVA (MPS...
-
Oct 28, 2008Well-Positioned for Continued Long-Term Growth
Financial Highlights ($ in millions, except per share data) Item Q3 2008 Q3 2007 Comparison Total BioMarin Revenue $72.6 190.5% increase Naglazyme Net Product Revenue $33.3 56.3% increase...
-
Oct 15, 2008Subjects Show Improvement in Endothelial Dysfunction
BioMarin Pharmaceutical Inc. today announced results from its Phase 2a multi-center, open-label, dose-escalation clinical study of 6R-BH4 in patients with sickle cell disease (SCD) designed to...
-
Oct 7, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 28, at 5:00 p.m. ET (23:00...
-
Oct 7, 2008
BioMarin Pharmaceutical Inc. announced today that it has opened a new office in Brisbane, California, to expand its drug development operations and better meet the increasing demands of the...
-
Sep 25, 2008Decision on Marketing Authorization Expected by End of 2008
BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received a positive opinion for Kuvan(R) (sapropterin dihydrochloride)...
-
Sep 18, 2008
BioMarin Pharmaceutical Inc. announced today several corrections to an article released by Bloomberg this morning. The article was based on a telephone interview with Jean-Jacques Bienaime, Chief...
-
Sep 11, 2008
BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Merrill Lynch Global...
-
Sep 2, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in...
-
Sep 2, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 3rd Annual Citi Biotech Day in New York City on...
-
Aug 21, 2008Conference Call and Webcast to Be Held Today at 4:30 p.m. ET (21:30 CET)
BioMarin Pharmaceutical Inc. announced today the roll-out of the national PKU Demographics, Outcomes and Safety Registry (PKUDOS). The registry is open to all PKU clinics within the United States,...
-
Aug 5, 2008Second Quarter Profit Driven by Strong Revenue Growth Improved Total Revenue Guidance
Financial Highlights ($ in millions, except per share data) Item Q2 2008 Q2 2007 Comparison Total BioMarin Revenue $64.2 122% increase Naglazyme Net Product Revenue $35.1 67.9% increase Aldurazyme...
-
Jul 22, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Summit Corporation plc (AIM: SUMM) announced today that they have entered into an exclusive worldwide licensing agreement for Summit's novel...
-
Jul 16, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo), has received marketing approval from the Japanese Ministry of...
-
Jul 15, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 5,...
-
Jul 1, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Collins Stewart Growth...
-
Jun 5, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio...
-
May 22, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) will host a Research and Development Day for the financial community on Thursday, June 5, 2008 from 7:30 a.m. to 11:30 a.m. at the W New York...
-
May 20, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine...
-
May 7, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Healthcare...
-
May 6, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the...
-
Apr 29, 2008First Quarter Profit Driven by Strong Revenue Growth
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the first quarter ended March 31, 2008. Net income was $1.7 million ($0.02 per share) for the first...
-
Apr 24, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global...
-
Apr 8, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, April 29,...
-
Mar 31, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has received approval for its Marketing...
-
Mar 12, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Lehman Brothers Global...
-
Mar 11, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the...
